Abbott Laboratories $ABT Shares Acquired by Dakota Wealth Management

Dakota Wealth Management increased its position in shares of Abbott Laboratories (NYSE:ABT) by 13.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 229,174 shares of the healthcare product maker’s stock after acquiring an additional 26,377 shares during the quarter. Dakota Wealth Management’s holdings in Abbott Laboratories were worth $28,713,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Charles Schwab Trust Co raised its position in shares of Abbott Laboratories by 109.8% during the 3rd quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock valued at $3,939,000 after buying an additional 15,394 shares during the period. Danica Pension Livsforsikringsaktieselskab acquired a new stake in Abbott Laboratories during the third quarter worth $185,640,000. Asset Management One Co. Ltd. raised its position in Abbott Laboratories by 2.4% in the third quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock valued at $115,032,000 after purchasing an additional 19,966 shares during the period. Nordea Investment Management AB lifted its stake in shares of Abbott Laboratories by 6.1% in the 3rd quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock valued at $43,785,000 after purchasing an additional 18,974 shares during the last quarter. Finally, AE Wealth Management LLC lifted its stake in shares of Abbott Laboratories by 20.8% in the 3rd quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock valued at $8,774,000 after purchasing an additional 11,264 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Activity

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the sale, the executive vice president directly owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. This represents a 0.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Eric Shroff sold 709 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the sale, the senior vice president owned 39,164 shares in the company, valued at $4,526,575.12. The trade was a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Stock Down 0.3%

Abbott Laboratories stock opened at $104.55 on Friday. The firm has a market capitalization of $182.10 billion, a P/E ratio of 28.11, a P/E/G ratio of 1.67 and a beta of 0.74. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a twelve month low of $102.41 and a twelve month high of $139.06. The stock’s fifty day simple moving average is $111.17 and its 200-day simple moving average is $122.32.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The firm had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. During the same period in the previous year, the firm posted $1.34 EPS. Abbott Laboratories’s revenue for the quarter was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is presently 67.74%.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on ABT shares. The Goldman Sachs Group cut their price objective on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Argus decreased their target price on shares of Abbott Laboratories from $150.00 to $140.00 in a research report on Tuesday, January 27th. Daiwa Securities Group dropped their price target on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. Royal Bank Of Canada decreased their price objective on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Finally, Barclays lowered their price objective on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research report on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $136.16.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.